{
    "clinical_study": {
        "@rank": "136152", 
        "acronym": "REFRAME", 
        "arm_group": {
            "arm_group_label": "Regorafenib", 
            "arm_group_type": "Experimental", 
            "description": "Regorafenib will be administered orally at the initial dosage of 160 mg per day for 3 weeks,followed by one week of rest, according to the 3/1 regimen."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy and safety of single-agent regorafenib\n      in the first line treatment of frail and/or unfit for polychemotherapy patients with\n      metastatic colorectal cancer (mCRC)"
        }, 
        "brief_title": "Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Colorectal Neoplasms", 
            "Metastatic Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Colorectal Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signing of the informed consent form.\n\n          2. The patient must be able to understand the information and state expressly his or her\n             desire to take part in the study.\n\n          3. Age > 18 years.\n\n          4. Patients with histologically or cytologically documented adenocarcinoma of the colon\n             or rectum who have not been previously treated systemically for advanced disease.\n             Patients can have received fluoropyrimidine-based adjuvant therapy if the last dose\n             was taken at least 6 months prior to study entry.\n\n          5. Patients who are frail and/or unfit for polychemotherapy owing to the presence of one\n             or more of the following criteria:\n\n               1. Patients with dependence in activities of daily living owing to the presence of\n                  comorbidities other than those resulting from the deterioration caused by the\n                  neoplastic disease.\n\n               2. Presence in the patient's medical history of three or more of the following\n                  comorbidities, even if they are under control with proper treatment:\n\n                    -  Congestive heart failure\n\n                    -  Other chronic cardiovascular diseases\n\n                    -  Chronic obstructive pulmonary disease\n\n                    -  Cerebrovascular disease\n\n                    -  Peripheral neuropathy\n\n                    -  Chronic kidney failure\n\n                    -  Hypertension\n\n                    -  Diabetes mellitus\n\n                    -  Systemic vasculitis\n\n                    -  Severe arthritis\n\n               3. Presence of geriatric syndromes such as age > 85 years, faecal or urinary\n                  incontinence, spontaneous bone fractures, mild and moderate dementia, or\n                  patients who fall repeatedly.\n\n          6. Existence of at least one measurable unidimensional lesion using CT or MRI based on\n             the Response Evaluation Criteria in Solid Tumors criteria (RECIST), version 1.1\n\n          7. Overall Eastern Cooperative Oncology Group (ECOG) performance less than or equal to 2\n\n          8. Patient's commitment to compliance with the oral medication throughout the duration\n             of the study\n\n          9. Life expectancy of at least 3 months\n\n         10. Adequate bone marrow, renal and hepatic function, defined as:\n\n               1. Neutrophils > 1500/mm3\n\n               2. Platelets > 100,000/mm3\n\n               3. Creatinine clearance > 30 ml/min\n\n               4. Hemoglobin \u2265 9 gr/dl\n\n               5. Bilirubin levels < 2.5 x ULN\n\n               6. Aspartate aminotransferase (AST) and alanine transaminase (ALT) levels < 3 x ULN\n                  (if liver metastases < 5 x ULN)\n\n        Exclusion Criteria:\n\n          1. Prior treatment with regorafenib.\n\n          2. Assignment prior to treatment during this study. Patients who are permanently\n             withdrawn from participation in the study treatment will not be allowed to return to\n             it.\n\n          3. Prior or concurrent presence of another neoplastic disease that is different in terms\n             of tumour site and histology of the colorectal cancer in the 5 years prior to the\n             inclusion of the patient in the study, except in situ cervical cancer, superficial\n             bladder carcinoma [Ta (non-invasive), Tis (carcinoma in situ) and T1 (tumour invades\n             lamina propria)] and non-melanoma skin tumours.\n\n          4. Presence or history of brain metastases or meningeal tumours.\n\n          5. Major surgery, open biopsy or traumatic injury within 28 days prior to the start of\n             patient treatment with the study medication.\n\n          6. Extended-field radiotherapy within 4 weeks prior to randomisation or limited-field\n             radiotherapy in the previous 2 weeks. Patients must have recovered from all\n             treatment-related toxicities.\n\n          7. Pregnant or breastfeeding women. Women of childbearing age must use adequate\n             contraception. Women of childbearing age must have a negative pregnancy test within 7\n             days prior to starting with the study medication.\n\n          8. Women of childbearing age and men who wish to take part in the study must agree to\n             use adequate contraception from the signing of the informed consent until at least 3\n             months after stopping the study medication. The investigator or the person designated\n             by him or her will ensure and advise as to the contraceptive methods that should be\n             used. Appropriate contraceptive methods include abstinence, oral contraceptives,\n             transdermal patches and injections of sustained-release progestin (starting at least\n             4 weeks before administration of the IMP), double-barrier method: condom or female\n             condom (diaphragm or cervical/vaginal condom) plus spermicide, intrauterine device\n             (IUD), intrauterine system, implant or vaginal ring (in place at least 4 weeks before\n             administration of the IMP) or male partner sterilization (vasectomy with\n             documentation of azoospermia) prior to inclusion of the woman in the trial if he is\n             the woman's only sexual partner.\n\n          9. Active congestive heart failure class 2 or higher on the New York Heart Association\n             (NYHA) scale.\n\n         10. Unstable angina (angina symptoms at rest), new-onset angina (having appeared in the\n             past 3 months) or acute myocardial infarction that has occurred in the 6 months prior\n             to starting with the study medication.\n\n         11. Cardiac arrhythmias that require anti-arrhythmic therapy (only beta blockers and\n             digoxin would be allowed as concomitant medication for these patients).\n\n         12. Uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic blood\n             pressure > 90 mmHg) despite proper medical management.\n\n         13. Patients with phaeochromocytoma.\n\n         14. Pleural effusion or ascites that cause breathing difficulties (dyspnoea of grade \u22652\n             of the CTC).\n\n         15. Accidents (including transient ischaemic attacks), deep vein thrombosis or pulmonary\n             thromboembolism that have occurred in the 6 months prior to starting with the study\n             medication.\n\n         16. Active infection > grade 2 based on the NCI CTC, v. 4.0.\n\n         17. Human immunodeficiency virus (HIV) infection.\n\n         18. Active hepatitis B or C, or hepatitis B or C infection that requires treatment with\n             antiviral drugs.\n\n         19. Patients with severe mental disorders that require medication.\n\n         20. Presence or history of brain metastases or meningeal tumours.\n\n         21. History of organ transplants.\n\n         22. Patients with evidence or history of bleeding diathesis. Any bleeding or bleeding\n             event > Common Toxicity Criteria for Adverse Effects (CTCAE) grade 3 in the 4 weeks\n             prior to starting with the study medication.\n\n         23. Presence of unhealed wounds, ulcers or bone fractures.\n\n         24. Kidney failure requiring haemodialysis or peritoneal dialysis.\n\n         25. Dehydration based on NCI CTC criteria, version 4, of > 1.\n\n         26. Substance abuse or a history of medical, social or psychological conditions that may\n             interfere with study participation or compliance with the efficacy and safety\n             assessments planned in the study.\n\n         27. Known hypersensitivity to regorafenib or any of its excipients.\n\n         28. Presence of any disease or medical condition that might interfere with patient safety\n             or may compromise treatment compliance with it.\n\n         29. Interstitial lung disease with signs and symptoms present at the time of signing the\n             informed consent.\n\n         30. Patients who are unable to swallow oral medication.\n\n         31. Persistent proteinuria > grade 3 based on the NCI CTC, version 4.0 (> 3.5 g/24\n             hours).\n\n         32. Intestinal malabsorption syndrome.\n\n         33. Close personal relationship with the research staff, such as family members of the\n             investigator or dependents (e.g. employees or students of the research centre).\n\n         34. Unresolved toxicity grade > 1 based on the NCI CTC, version 4.0 (except alopecia),\n             related to any previous therapy or procedure."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "46", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01875380", 
            "org_study_id": "TTD-13-01", 
            "secondary_id": "2013-000236-94"
        }, 
        "intervention": {
            "arm_group_label": "Regorafenib", 
            "intervention_name": "Regorafenib", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "metastatic colorectal cancer", 
            "frail and unfit patient", 
            "regorafenib"
        ], 
        "lastchanged_date": "March 26, 2014", 
        "link": {
            "url": "http://www.ttdgroup.org"
        }, 
        "location": {
            "contact": {
                "email": "ttd@ttdgroup.org", 
                "last_name": "Inmaculada Ruiz de Mena, PhD", 
                "phone": "0034 91 378 82 75"
            }, 
            "facility": {
                "address": {
                    "city": "Madrid", 
                    "country": "Spain", 
                    "zip": "28046"
                }, 
                "name": "Spanish Cooperative Group for Digestive Tumour Therapy (TTD)"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of Single-agent Regorafenib in the First Line Treatment of Frail and/or Unfit for Polychemotherapy Patients With Metastatic Colorectal Cancer (mCRC)", 
        "other_outcome": [
            {
                "measure": "microRNA expression levels and their correlation with tumour-efficacy parameters (objective response rate, progression-free survival and overall survival), as well as toxicity", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "measure": "Biomarkers associated with cell and tumour growth and/or the mechanism of action of regorafenib and their correlation with patients' clinical progression for efficacy and safety parameters.", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }
        ], 
        "overall_contact": {
            "email": "ttd@ttdgroup.org", 
            "last_name": "Inmaculada Ruiz de Mena, PhD", 
            "phone": "00 34 91 378 82 75"
        }, 
        "overall_official": [
            {
                "affiliation": "Ramon y Cajal University Hospital", 
                "last_name": "Alfredo Carrato, MD-PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Ramon y Cajal University Hospital", 
                "last_name": "Enrique Grande, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival rate at 6 months", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01875380"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "measure": "Disease control rate", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "measure": "Time to response", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "measure": "Time to treatment failure", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "measure": "Response duration", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "measure": "Duration of stable disease", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "measure": "Incidence and severity of Adverse Events (NCI CTC, version 4.0)", 
                "safety_issue": "Yes", 
                "time_frame": "30 months"
            }, 
            {
                "measure": "Changes in laboratory values (transaminases, bilirubin, lactate dehydrogenase (LDH), anaemia,neutropenia and thrombocytopenia)", 
                "safety_issue": "Yes", 
                "time_frame": "30 months"
            }, 
            {
                "measure": "Change in vital signs (weight loss and hypertension)", 
                "safety_issue": "Yes", 
                "time_frame": "30 months"
            }, 
            {
                "measure": "Incidence of dose adjustments and compliance", 
                "safety_issue": "Yes", 
                "time_frame": "30 months"
            }, 
            {
                "measure": "Incidence of concomitant medication", 
                "safety_issue": "Yes", 
                "time_frame": "30 months"
            }, 
            {
                "measure": "Changes in ECOG performance status over time from baseline", 
                "safety_issue": "Yes", 
                "time_frame": "30 months"
            }
        ], 
        "source": "Spanish Cooperative Group for Digestive Tumour Therapy (TTD)", 
        "sponsors": {
            "collaborator": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Spanish Cooperative Group for Digestive Tumour Therapy (TTD)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}